Drug Profile
Research programme: antibody targeted amanitin conjugates - Heidelberg Pharma Research
Alternative Names: anti-CD19-amanitin conjugate; anti-CD269-amanitin conjugate; ATACs - Heidelberg Pharma Research/Roche; BCMA-amanitin conjugate; CD 19 - ATAC; Her-DSC 30-0134Latest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Heidelberg Pharma
- Developer Heidelberg Pharma AG; Heidelberg Pharma Research; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action DNA-directed RNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Burkitt's lymphoma; Colorectal cancer; Triple negative breast cancer
Most Recent Events
- 15 Nov 2023 Heidelberg Pharma Research has patent protection for site-specific ATAC conjugates in Europe
- 28 Apr 2023 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in Germany (SC)
- 08 Apr 2022 Pharmacodynamics data from preclinical trials in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)